Edition:
United States

ARMO Biosciences Inc (ARMO.OQ)

ARMO.OQ on NASDAQ Stock Exchange Global Select Market

49.98USD
21 Jun 2018
Change (% chg)

-- (--)
Prev Close
$49.98
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
105,289
52-wk High
$57.00
52-wk Low
$25.14

Select another date:

Wed, May 23 2018

BRIEF-Eli Lilly's Unit, Bluegill Acquisition Offering To Buy All Of Armo Biosciences's Outstanding Shares For $50/Share

* ARMO BIOSCIENCES - ELI LILLY'S UNIT, BLUEGILL ACQUISITION CORP, OFFERING TO BUY ALL OF CO'S OUTSTANDING SHARES FOR $50/SHARE - SEC FILING

BRIEF-HBM Healthcare Investments: Eli Lilly Announces Tender Offer For HBM-Portfolio Company

* ELI LILLY ANNOUNCES TENDER OFFER FOR HBM-PORTFOLIO COMPANY ARMO BIOSCIENCES FOR USD 1.6 BILLION

Lilly to buy Armo Biosciences for $1.6 billion to bolster cancer pipeline

Eli Lilly and Co said on Thursday it would buy Armo BioSciences Inc for about $1.6 billion to expand its portfolio of drugs that helps body's immune system fight cancer as the U.S. drugmaker chases rivals in a lucrative market.

UPDATE 3-Lilly to buy Armo Biosciences for $1.6 bln to bolster cancer pipeline

* Armo's lead drug has presented data for several cancer types

BRIEF-Lilly Announces Agreement To Acquire Armo Biosciences

* ARMO BIOSCIENCES INC - LILLY WILL COMMENCE TENDER OFFER TO ACQUIRE ALL SHARES OF ARMO FOR PURCHASE PRICE OF $50 PER SHARE IN CASH

Lilly to buy Armo Biosciences for $1.6 bln

May 10 Drugmaker Eli Lilly and Co said on Thursday it would buy Armo BioSciences Inc for about $1.6 billion to get access to the drug developer's experimental cancer treatment.

BRIEF-Armo Biosciences Enrolls Patient In The Cypress 2 Trial Evaluating AM0010

* ARMO BIOSCIENCES ENROLLS FIRST PATIENT IN THE CYPRESS 2 TRIAL EVALUATING AM0010 IN NON-SMALL CELL LUNG CANCER Source text for Eikon: Further company coverage:

BRIEF-Armo Biosciences Announces Positive Outcome Of First Interim Analysis In Sequoia Phase 3 Pancreatic Cancer Study

* ARMO BIOSCIENCES ANNOUNCES POSITIVE OUTCOME OF FIRST INTERIM ANALYSIS IN SEQUOIA PHASE 3 PANCREATIC CANCER STUDY

BRIEF-ARMO Biosciences Sees IPO Of Up To 6.7 Mln Shares Of Common Stock, Estimated IPO Price Between $14 And $16/Shr

* ARMO BIOSCIENCES INC SEES IPO OF UP TO 6.7 MILLION SHARES OF COMMON STOCK AND ESTIMATED IPO PRICE BETWEEN $14.00 AND $16.00 PER SHARE - SEC FILING

Select another date: